ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Charlotte, NC, USA:

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Charlotte, North Carolina, United States and 137 other locations

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trast...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Neoplasms
Drug: Oxaliplatin
Drug: Cisplatin

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 191 other locations

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced...

Enrolling
Endometrial Adenocarcinoma
Appendiceal Adenocarcinoma
Drug: APL-5125

Phase 1, Phase 2

Apollo Therapeutics

Huntersville, North Carolina, United States and 2 other locations

Locations recently updated

This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It...

Enrolling
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Drug: oxaliplatin
Drug: trastuzumab

Phase 1, Phase 2

Seagen
Seagen

Charlotte, North Carolina, United States and 21 other locations

Locations recently updated

a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, gastroesophageal adenocarcinoma...

Enrolling
Gastroesophageal Adenocarcinoma
Advanced Solid Tumors
Drug: ABBV-400
Drug: Trifluridine/Tipiracil

Phase 1

AbbVie
AbbVie

Huntersville, North Carolina, United States of America and 81 other locations

This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.

Enrolling
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Huntersville, North Carolina, United States and 6 other locations

adenocarcinoma. Enrollment in the expansion cohorts is limited to the following tumor types: endometrial, SCCHN, CRC, and a basket cohort i...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: TPST-1495 once daily or on intermittent schedule
Drug: Pembrolizumab

Phase 1

Tempest Therapeutics

Huntersville, North Carolina, United States and 10 other locations

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy...

Enrolling
Solid Tumors
Drug: INCB0123667

Phase 1

Incyte
Incyte

Huntersville, North Carolina, United States and 33 other locations

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Drug: Bemarituzumab
Drug: mFOLFOX6

Phase 3

Amgen
Amgen

Charlotte, North Carolina, United States and 300 other locations

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with ad...

Enrolling
Esophageal Adenocarcinoma
Metastatic Cancer
Drug: TJ033721, nivolumab, chemotherapy
Drug: TJ033721

Phase 1

I-Mab Biopharma

Huntersville, North Carolina, United States of America and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems